CJC-1295 Buyer's Guide: 4 Decisions Before You Buy

Most people buying CJC-1295 make the same four decisions wrong, not because the information isn't out there, but because nobody explains the underlying biology that makes each decision matter. So before you spend money on any of this, here is the system you need to understand.

Growth hormone doesn't just sit at a steady level in your blood. Your pituitary releases it in sharp pulses, and those pulses are what drive most of the downstream effects you actually want, like IGF-1 production, fat metabolism, and tissue repair. The height and sharpness of those pulses matter because the pituitary gland responds to contrast. A sharp spike followed by a return to baseline is what keeps the system sensitive and responsive. This is why the entire category of compounds called secretagogues, which are molecules that stimulate your own glands to secrete hormones rather than replacing the hormones directly, exists as an alternative to exogenous growth hormone. The goal is to amplify your natural pulses without flattening the pattern.

That context makes the first decision obvious.

CJC-1295 comes in two forms. One is CJC-1295 with DAC, where DAC stands for Drug Affinity Complex, which is a modification that lets the molecule bind to albumin proteins circulating in your blood. That binding extends the half-life from a few minutes to roughly seven days, which sounds convenient because you only need to inject once or twice a week. But the reason that extended half-life exists is that the molecule is now continuously present in your system, which means you are getting a flat, steady elevation of GHRH signaling instead of pulses. You have taken a tool designed to sharpen your natural pulsatile pattern and turned it into a continuous drip. If you want flat growth hormone elevation, exogenous growth hormone does exactly that and carries decades of clinical data behind it. CJC-1295 without DAC, the version with a half-life closer to 30 minutes, is the only version that preserves the pulsatile mechanism you are trying to support. No DAC is the only version worth buying.

The second decision is about whether to buy a blend or separate vials, and this one is mostly about math.

A common product on the research peptide market is a vial containing both CJC-1295 without DAC and Ipamorelin in a single blend, often 5 milligrams of each in the same vial. When you reconstitute that with 2 milliliters of bacteriostatic water, every 10 units on an insulin syringe delivers 250 micrograms of each compound simultaneously. If your protocol calls for different doses of each, a blend forces you into a fixed ratio and removes that flexibility. Separate vials let you adjust each independently, which matters more as you understand how the two compounds work differently.

Which leads directly to the third decision: cycling.

CJC-1295 and Ipamorelin are almost always paired together because they work through two completely separate receptor pathways, and stimulating both at once produces a significantly larger GH pulse than either alone. CJC-1295 works through something called GHRH receptors, which are growth hormone releasing hormone receptors that sit on pituitary cells and respond to the same signal your hypothalamus naturally sends. Ipamorelin works through something called GHSR1a, which is the ghrelin receptor, a completely separate pathway that also triggers GH release but through a different mechanism involving a signaling protein called beta-arrestin.

Here is where the cycling question gets interesting.

Those two receptor types behave differently under prolonged stimulation. The GHRH receptor pathway does not appear to desensitize meaningfully with continuous use. The FDA ran tesamorelin, a GHRH analog similar in mechanism to CJC-1295 without DAC, continuously for 52 weeks in clinical trials and IGF-1 levels held steady through the entire duration with no significant drop from the levels observed at week 26. That is a year of continuous stimulation with no meaningful receptor downregulation.

The ghrelin receptor pathway is a different story. Research on GHSR1a desensitization shows that beta-arrestin mediated internalization pulls receptors off the cell surface with prolonged stimulation, which is the cellular mechanism for a process called downregulation, meaning your cells physically reduce the number of available receptors so the same signal produces less response. In practical terms, after about 12 to 16 weeks of continuous Ipamorelin use, IGF-1 levels can drop 20 to 30 percent from their peak even without any change in dose. You are injecting the same amount and getting less output because the receptors have adapted.

The standard cycling protocol of three months on, one month off exists entirely because of this ghrelin receptor desensitization and has nothing to do with the CJC side of the equation. The month off allows receptor density to recover so you return to full sensitivity when you restart. If you were running CJC-1295 without DAC alone, there is no strong biological case for aggressive cycling based on what the tesamorelin data shows. The cycle is driven by the Ipamorelin. That distinction matters if you ever adjust your protocol.

The fourth decision is knowing when to stop using secretagogues entirely and switch to exogenous growth hormone.

Secretagogues work within your biological ceiling. Your pituitary can only release as much growth hormone as it is capable of producing, and the feedback loop that regulates the whole system stays intact, meaning your body can still self-regulate. Exogenous growth hormone pushes past that ceiling by delivering growth hormone directly into circulation regardless of what your pituitary is doing. These two approaches are not compatible to run simultaneously, and the reason is measurable.

After a single injection of exogenous growth hormone, somatostatin, which is the body's main inhibitory brake on growth hormone release, suppresses the GHRH pathway by 86 percent. That means if you inject growth hormone in the morning and then inject CJC-1295 that evening, the CJC is trying to stimulate a pathway that has been almost entirely shut down. You are paying for a compound that cannot do its job. When your goals require more growth hormone than your body can produce on its own, you drop the secretagogues and transition to growth hormone. Running both is not additive. It is wasteful.

Most people frame this as "which is better," but that is the wrong question. Secretagogues and growth hormone are tools for different situations, not competitors. The secretagogue approach preserves your body's regulatory infrastructure and works well when your natural production capacity is still meaningful. Growth hormone replaces that infrastructure entirely and makes sense when you need output beyond what that system can deliver. Understanding where you sit on that spectrum is the real decision underneath all four of these choices.

---

References

1. FDA Prescribing Information. EGRIFTA (tesamorelin). 2025 — 52-week continuous dosing, IGF-1 levels maintained at week-26 levels through week 52
2. Bowers CY et al. On the in vitro and in vivo activity of a new synthetic hexapeptide. Endocrinology. 1984 — GHRP/ghrelin receptor agonist mechanism
3. PNAS. Discovery of a functionally selective ghrelin receptor (GHSR1a) ligand. 2022 — β-arrestin mediated GHSR1a desensitization mechanism
4. Veldhuis JD et al. Somatostatin inhibition of GHRH-stimulated GH secretion. J Clin Endocrinol Metab — 86% GHRH pathway inhibition after exogenous GH
5. Falutz J et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. NEJM. 2007 — Tesamorelin 26-week clinical trial efficacy

---

Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness